Bristol Myers Squibb (BMY) Other Operating Expenses (2009 - 2026)

Bristol Myers Squibb has disclosed Other Operating Expenses across 18 years of filings, most recently posting $4.0 billion for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 9.23% year-over-year to $4.0 billion; the TTM figure through Mar 2026 stood at $21.2 billion (down 8.34% YoY), while the FY2025 annual figure was $21.6 billion, down 41.66% from the prior year.
• Other Operating Expenses slipped to $4.0 billion in Q1 2026, from $6.3 billion in the prior quarter.
• Over the last five years, Other Operating Expenses for BMY reached as high as $18.3 billion in Q1 2024 and fell as low as $4.0 billion in Q1 2026.
• The 5-year median for Other Operating Expenses is $5.3 billion (2023), against an average of $6.1 billion.
• Annual changes were most pronounced in 2024 — Other Operating Expenses surged 308.54% — and 2025, when it plunged 76.04%.
• A 5-year view of Other Operating Expenses shows it stood at $4.8 billion in 2022, then increased by 10.08% to $5.3 billion in 2023, then soared by 30.24% to $6.8 billion in 2024, then decreased by 8.41% to $6.3 billion in 2025, then slumped by 36.41% to $4.0 billion in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $4.0 billion, $6.3 billion, and $4.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.